Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-397, Potent Small Molecule For Treatment Of Anxiety And Alzheimer's Disease

San Diego, CA – June 22nd, 2009 - Avineuro Pharmaceuticals, Inc. announced today an initiation of a two-armed, double-blinded, placebo- and a reference drug- controlled Phase II clinical studies of AVN-397, a potent small molecule for treatment of anxiety and Alzheimer’s disease. Avineuro Pharmaceuticals, Inc. will present at ICAD 2009 in Vienna, Austria in July.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.